New data from CGT Catapult has demonstrated progression by the industry toward commercialization of therapies and an increase in GMP manufacturing space. New data from the Cell and Gene Therapy ...

CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...

TrakCel solution integration with Cell and Gene Therapy Catapult manufacturing centre enables needle-to-needle supply chain management at any scale The Cell and Gene Therapy Catapult (CGT Catapult) ...

LONDON, October 06, 2025--(BUSINESS WIRE)--Mytos, a biotechnology company automating cell manufacturing, today announced the launch of its automated contract development and manufacturing organization ...

LONDON, Sept. 23, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the ...

Quell Therapeutics Ltd (Quell), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announced it has entered a ...

TrakCel said today it will incorporate its needle-to-needle supply chain management platform into the Cell and Gene Therapy (CGT) Catapult’s large-scale cell and gene therapy manufacturing center set ...

LONDON--(BUSINESS WIRE)--Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a ...

On March 11, 2021, Cell and Gene Therapy Catapult (CGT Catapult) announced that GlaxoSmithKline (GSK) will expand its clinical trial manufacturing capacity for cell and gene therapies at CGT ...

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...

Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell's pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and ...